Effects of thalidomide treatment in heart failure patients

Cardiology

Volumn 108, Issue 4, 2007, Pages 237-242

  Orea Tejeda, Arturo ^a   Arrieta Rodríguez, Oscar ^b   Castillo Martínez, Lilia ^a,c   Rodríguez Reyna, Tatiana ^a   Asensio Lafuente, Enrique ^a   Granados Arriola, Julio ^a   Dorantes García, Joel ^a  

^a INSTITUTO NACIONAL DE CIENCIAS MÉDICAS Y NUTRICIÓN SALVADOR ZUBIRÁN   (Mexico)

^b INSTITUTO NACIONAL DE CANCEROLOGÍA   (Mexico)

^c NONE   (Mexico)

Author keywords

Anti TNF therapy; Heart failure; Thalidomide treatment

Indexed keywords

THALIDOMIDE; TUMOR NECROSIS FACTOR ALPHA;

ADULT; ANOREXIA; ARTICLE; BLOOD LEVEL; CARDIOMYOPATHY; CLINICAL ARTICLE; CLINICAL TRIAL; COMORBIDITY; CONSTIPATION; CONTROL GROUP; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG DOSE REDUCTION; DRUG EFFECT; ECHOCARDIOGRAPHY; FEMALE; FOLLOW UP; HEART FAILURE; HUMAN; LABORATORY TEST; MALE; NAUSEA; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SEX DIFFERENCE; SINUS BRADYCARDIA; SYSTOLIC DYSFUNCTION; XEROSTOMIA;

AGED; BIOLOGICAL MARKERS; CARDIOVASCULAR AGENTS; FEMALE; HEART FAILURE; HUMANS; MALE; MIDDLE AGED; PROSPECTIVE STUDIES; THALIDOMIDE; TUMOR NECROSIS FACTOR-ALPHA;

EID: 34249083237     PISSN: 00086312     EISSN: None     Source Type: Journal    
DOI: 10.1159/000096829     Document Type: Article

References (35)

1. Grady KL, Dracup K, Kennedy G, Moser DK, Piano M, Stevenson LW, Young JB: Team Management of patients with heart failure. Circulation 2000;102:2443-2456.
2. Mann DL: Inflammatory mediators and the failing heart: past,present and the foreseeable future. Circ Res 2002;91:988-998.
3. von Haehling S, Anker SD: Future prospects of anticytokine therapy in chronic heart failure. Expert Opin Investig Drugs 2005;14:163-176.
4. Testa M, Yeh M, Lee P, et al: Circulating levels of cytokines and their endogenous modulators in patients with mild to severe congestive heart failure due to coronary artery disease or hypertension. J Am Coll Cardiol 1996;28:964-971.
5. Torre-Amione G, Kapadia S, Benedict C, et al: Proinflammatory cytokine levels in patients with depressed left ventricular ejection fraction: a report from the studies of left ventricular dysfunction (SOLVD). J Am Coll Cardiol 1996;27:1201-1206.
6. Munger MA, Johnson B, Amber IJ, et al: Circulating concentrations of proinflammatory cytokines in mild or moderate heart failure secondary to ischemic or idiopathic dilated cardiomyopathy. Am J Cardiol 1996;77:423-427.
7. Yamaoka-Tojo M, Tojo T, Inomata T, et al: Circulating levels of interleukin 18 reflect etiologies of heart failure: Th1/Th2 cytokine imbalance exaggerates the pathophysiology of advanced heart failure. J Card Fail 2002;8:21-27.
8. Damås JK, Gullestad L, Aass H, et al: Enhanced gene expression of chemokines and their corresponding receptors in mononuclear blood cells in chronic heart failure modulatory effects of intravenous inmunoglobulin. J Am Coll Cardiol 2001;38:187-193.
9. Torre-Amione G, Kapadia S, Lee J, et al: Tumor necrosis factor- and tumor necrosis factor receptors in the failing human heart. Circulation 1996;93:704-711.
10. Deveaux B, Scholz D, Hirche A, et al: Upregulation of cell adhesion molecules and the presence of low grade inflammation in human chronic heart failure. Eur Heart J 1997;18:470-479.
11. Damås JK, Eiken HG, Øie E, et al: Myocardial expression of CC- and CXC-chemokines and their receptors in human endstage heart failure. Cardiovasc Res 2000;47:778-787.
12. Eiken HG, Øie E, Damås JK, et al: Myocardial gene expression of leukemia inhibitory factor, interleukin-6 and glycoprotein 130 in end-stage human heart failure. Eur J Clin Invest 2001;31:389-397.
13. Birks EJ, Owen VJ, Bruton PB, Bishop AE, Banner NF, Khaghani A, Polak JM, Yacoub MH: Tumor necrosis factor alfa is expressed in donor heart and predicts right ventricular failure after human heart transplantation. Circulation 2000;102:326-331.
14. Bryant D, Becker L, Richarson J, Shelton J, Franco F, Peshock R: Cardiac failure in transgenic mice with myocardial expression of tumor necrosis factor. Circulation 1998;97:1375-1381.
15. Aukrust P, Ueland T, Muller F, et al: Elevated circulating levels of C-C chemokines in patients with congestive heart failure. Circulation 1998;97:1136-1143.
16. Damås JK, Gullestad L, Ueland T, et al: CXC-chemokines, a new group of cytokines in congestive heart failure-possible role of platelets and monocytes. Cardiovasc Res 2000;45:428-436.
17. Dibbs Z, Kurrelmeyer K, Kalra D: Cytokines in heart failure: pathogenic mechanisms and potential treatment. Proc Assoc Am Physicians 1999;111:423-428.
18. Sharma R, Coats AJ, Anker SD: The role of inflammatory mediators in chronic heart failure: cytokine, nitric oxide and endothelin-1. Int J Cardiol 2000;72:175-186.
19. Kubota T, Bounoutas GS, Miyagishima M, Kadokami T, Sanders VJ, Bruto C, Robbins PD, Mc Tiernan CF, Feldman AM: Soluble tumor necrosis factor receptor abrogates myocardial inflammation but not hypertrophy in cytokine-induced cardiomyopathy. Circulation 2000;101:2518-2525.
20. Feldman AM, McTiernan C: Is there any future for tumor necrosis factor antagonists in chronic heart failure? Am J Cardiovasc Drugs 2004;1:11-19.
21. Davey PP, Ashrafian H, et al: New therapies for heart failure: is thalidomide the answer? QJM 2000;93:305-311.
22. Adlard JW: Thalidomide in the treatment of cancer. Anticancer Drugs 2000;11:787-791.
23. Gullestad L, Semb AG, Holt E, et al: Effect of thalidomide in patients with chronic heart failure. Am Heart J 2002;144:847-850.
24. Hunt SA, Baker DW, Chin MH, Ciquegrani MP, et al: ACC/AHA guidelines for the evaluation and management of chronic heart failure in the adult: executive summary: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines. Circulation 2001;104:2996-3007.
25. Remme WJ, Swedberg K, et al; Task Force for the Diagnosis and Treatment of Chronic Heart Failure, European Society of Cardiology: Guidelines for the diagnosis and treatment of chronic heart failure. Eur Heart J 2001;22:1527-1560.
26. Sotelo J, Guevara P, Reyes S, Arrieta O: Interstitial quinacrine for elimination of abnormal tissue; therapy of experimental glioma. Surgery 2000;128:439-446.
27. Milani RV, Mehra MR, Endres S, Eigler A, Cooper ES, Lavie CJ, et al: The clinical relevance of circulating tumor necrosis factor alpha in acute decompensated chronic heart failure without caquexia. Chest 1996;110:992-995.
28. Prabhu SD, Chandrasekar B, Murray DR, Freeman GL: Beta-adrenergic blockade in developing heart failure: effects on myocardial inflammatory cytokines, nitric oxide, and remodeling. Circulation 2000;101:2103-2109.
29. Hernandez-Presa M, Bustos C, Ortega M, Tunon J, Renedo G, Ruiz-Egido J: Angiotensin-converting enzyme inhibition prevents arterial factor-kappa B activation, monocyte chemoattractant protein-1 expression, and macrophage infiltration in a rabbit model of accelerated atherosclerosis. Circulation 1997;95:1532-1541.
30. Soejima H, Ogawa H, Yasue H, Kaikita K, Takazoe K, Nishiyama K, Miyamoto S, Yoshimura M, Kugiyama K, Tsuji I: Angiotensin-converting enzyme inhibitin reduces monocyte chemoattractant protein-1 and tissue factor levels in patients with myocardial infarction. J Am Coll Cardiol 1999;34:983-988.
31. Agoston I, Dibbs Z, Wang F, Muller G, Zeldis J, Mann D, Bozkurt B: Preclinical and clinical assessment of the safety and potential efficacy of thalidomide in heart failure. J Card Fail 2002;8:306-314.
32. Gullestas L, Ueland T, Fjeld JG, Holt E, Gurdensen T, Breivik K, et al: Effecto of thalidomide on cardiac remodeling in chronic heart failure. Results of a double-blind, placebo-controlled study. Circulation 2005;112:3408-3414.
33. Jacobsen JM: Thalidomide: a remarkable comeback. Expert Opin Pharmacother 2000;1:849-863.
34. Grabie N, Hsieh DT, Buono C, Westrich JR, Allen JA, Png H, et al: Neutrophils sustain pathogenic CD8+ T cell response in the heart. Am J Pathol 2003;163:2413-2420.
35. Afanasyeva M, Georgopoulos D, Belardi DF, Ramsundar AC, Kass l, Rose NR: Quantitative analysis of myocardial inflammation by flow cytometry in murine autoimmune myocarditis: correlation to cardiac function. Am J Pathol 2004;164:807-815.